Depreciation of Ovid Therapeutics Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Ovid Therapeutics Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Ovid Therapeutics Inc. Depreciation for the quarter ending 30 Sep 2025 was $17,000, a 84% decline year-over-year.
  • Ovid Therapeutics Inc. Depreciation for the twelve months ending 30 Sep 2025 was $256,000, a 35% decline year-over-year.
  • Ovid Therapeutics Inc. annual Depreciation for 2024 was $400,000, unchanged from 2023.
  • Ovid Therapeutics Inc. annual Depreciation for 2023 was $400,000, a 25% increase from 2022.
  • Ovid Therapeutics Inc. annual Depreciation for 2022 was $319,173, a 315% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Ovid Therapeutics Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $256,000 $17,000 -$88,000 -84% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $344,000 $61,000 -$42,000 -41% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $386,000 $87,000 -$14,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $400,000 $91,000 +$8,000 +9.6% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $392,000 $105,000 +$1,000 +0.96% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $391,000 $103,000 -$2,000 -1.9% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $393,000 $101,000 -$7,000 -6.5% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $400,000 $83,000 -$48,632 -37% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $448,632 $104,000 +$1,929 +1.9% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $446,703 $105,000 +$50,369 +92% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $396,334 $108,000 +$77,161 +250% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $319,173 $131,632 +$108,092 +459% 01 Oct 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
Q3 2022 $211,081 $102,071 +$85,574 +519% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $125,507 $54,631 +$36,797 +206% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $88,710 $30,839 +$11,839 +62% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $76,871 $23,540 +$5,540 +31% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
Q3 2021 $71,331 $16,497 +$1,497 +10% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $69,834 $17,834 +$2,834 +19% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $67,000 $19,000 +$7,000 +58% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $60,000 $18,000 +$8,000 +80% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $52,000 $15,000 +$5,000 +50% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $47,000 $15,000 +$6,000 +67% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $41,000 $12,000 +$2,000 +20% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $39,000 $10,000 $0 0% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
Q3 2019 $39,000 $10,000 +$3,000 +43% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $36,000 $9,000 $0 0% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $36,000 $10,000 +$1,000 +11% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $35,000 $10,000 +$2,238 +29% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $32,762 $7,000 -$171 -2.4% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $32,933 $9,000 +$2,345 +35% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $30,588 $9,000 +$3,671 +69% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $26,917 $7,762 +$2,899 +60% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 $24,018 $7,171 +$2,799 +64% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $21,219 $6,655 +$2,662 +67% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $18,557 $5,329 +$2,268 +74% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $16,289 $4,863 01 Oct 2016 31 Dec 2016 10-K 29 Mar 2018 2017 FY
Q3 2016 $4,372 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $3,993 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $3,061 01 Jan 2016 31 Mar 2016 10-Q 13 Jun 2017 2017 Q1

Ovid Therapeutics Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $400,000 $0 0% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $400,000 +$80,827 +25% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $319,173 +$242,302 +315% 01 Jan 2022 31 Dec 2022 10-K 08 Mar 2024 2023 FY
2021 $76,871 +$16,871 +28% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
2020 $60,000 +$21,000 +54% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $39,000 +$4,000 +11% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2021 2020 FY
2018 $35,000 +$8,083 +30% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $26,917 +$10,628 +65% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
2016 $16,289 +$12,386 +317% 01 Jan 2016 31 Dec 2016 10-K 29 Mar 2018 2017 FY
2015 $3,903 01 Jan 2015 31 Dec 2015 10-K 29 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.